Our Microscope and ViewPoint in Use for Research in Fertility Feasibility in Transwomen
Dennis Vermeulen
Business Development at PreciPoint. Supports customers in the digitization of their laboratories throughout Germany.
- February 8, 2023
- 12:29 pm
- Scientific publications
The study aimed to evaluate the feasibility of fertility preservation in pre-pubertal individuals undergoing gender-affirming hormone therapy. The established method of cryopreservation of immature testicular tissue, containing a population of diploid spermatogonia, is utilized as a means of preserving the spermatogenic potential of these individuals. A retrospective analysis of testicular tissue from 25 selected subjects was performed, who received a comparable hormonal regimen utilizing cyproterone acetate and estrogens.
Jennifer Dabel et al.
Abstract:
“Germ cells of transwomen are affected by gender-affirming hormone therapy (GAHT). Fertility will be lost after surgical intervention; thereby, fertility preservation becomes an increasingly important topic. This study investigated if the absolute number of spermatogonia in transwomen is comparable at the time of gender-affirming surgery (GAS) to that in pre-pubertal boys.”
What Were PreciPoint Products Used For?
For the analysis of tissue and measurement of germ cells, the researchers used our digital microscope equipped with a 60x objective. Researchers analyzed two independent MAGE A4-stained tissue sections. The samples were then viewed using ViewPoint software, which was used to identify and count all MAGE A4-positive and -negative spermatogonia within each sample.
Where can I find the publication?
To read the entire publication, click on:
New perspectives on fertility in transwomen with regard to spermatogonial stem cells.
